New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—
Dec '25 Dec '24
Current Ratio
9.20 6.07
Net Debt/EBITDA
1.70 0.51
Debt/Assets
0.00% 0.00%
Debt/Equity
0.00 0.00
Operating CF/Net income
0.79 0.21
Capex/Depreciation
(1.12) (5.05)
ROE
115.10% —
ROA
(84.47%) —
ROIC
0.00% 0.00%
Return on Tangible Assets
(61.07%) (201.32%)
Intangible Assets out of Total Assets
0.06 0.00
Free Cash Flow per Share
(12.07) (2.05)
Cash per Share
25.93 4.90
Shareholders Equity per Share
(19.35) (8.25)
Interest Debt per Share
0.00 0.00
Book value per Share
(19.35) (8.25)
Free Cash Flow
(156.20) (20.63)
Working Capital
307.82 42.03
Capital Expenditures
(5.14) (1.80)
Net Current Asset Value
(295.92) (96.40)
Other line items
Quick Ratio
8.94 5.96
Depreciation/Fixed assets
0.70 0.18
Cash ROIC
(183.44%) 61.05%
Operating CF per Share
(11.68) (1.87)
Capex per Share
(0.40) (0.18)
Average Payables
5.93 —
Average Assets
227.23 —
Average Common Equity
(166.76) —

Fold the line items

Columns are period end dates · fundamentals updated Nov 18, 2026